HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E1028 POMHEX POMHEX, is a potent ENO2 -specific inhibitor of enolase and a racemic mixture, a cell-permeable pivaloyloxymethyl (POM) prodrug of HEX. It is also glycolysis inhibitor and can be used for the research of cancer. Dec 13 2023
E1203 Sirpiglenastat Sirpiglenastat (DRP-104) is a broad acting glutamine antagonist. It has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response with immunomodulatory and antineoplastic activities. Dec 13 2023
S8091 25-Hydroxycholesterol 25-Hydroxycholesterol is a side-chain oxysterol and a selective suppressor of IgA production by B cells with an EC50≈65 nM. It affects the immune system and has a key role in the pathogenesis of atherosclerosis. Dec 12 2023
E1409 Zidesamtinib Zidesamtinib (NVL-520) is a potent brain-penetrating inhibitor of ROS1 tyrosine kinase with IC50 of 0.7 nM for wild-type ROS1 . It acts as a potential antineoplastic agent and can be used for the research of cancer. Dec 11 2023
S8395 INDY INDY, a benzothiazole derivative is a potent and ATP-competitive inhibitor of Dyrk1A and Dyrk1B with an IC50 value of 0.24 μM and Ki value of 0.18 μM, respectively. INDY diminishes the self-renewal capacity of normal and tumorigenic cells in primary Glioblastoma (GBM) cell lines and neural progenitor cells. Dec 11 2023
E1636 MV1035 MV1035, an inhibitor of ALKBH5 significantly reduces GBM U87-MG cell migration and invasiveness through inhibition of the RNA demethylase ALKBH5. Dec 11 2023
E1598 VT103 VT103 is an orally active and selective inhibitor of TEAD1 protein palmitoylation with anti-proliferative and anti-tumor activity. It also inhibits YAP/TAZ-TEAD promoted gene transcription, blocks TEAD auto-palmitoylation and disrupts interaction between YAP/TAZ and TEAD. Dec 07 2023
E1735 PK11007 PK11007 is a thiol-reactive anticancer agent that stabilizes p53 via selective alkylation of two surface cysteines without compromising its DNA binding. It induces mutant p53 cancer cell death by increasing reactive oxygen species (ROS) levels. Dec 07 2023
E1684 C1632 C1632 (Lin28-let-7 antagonist 1) is a RNA-binding protein and a potent antagonist of Lin28/pre-let-7 interaction. It inhibits Lin28A binding to pre-let-7a-2, with an IC50 of 8 μM as well as inhibits proliferation in human cancer cells. Dec 07 2023
E1512 M3541 M3541 is a potent and selective inhibitor of ATM kinase activity with an IC50 value of 0.25 nM in cell-free assays. M3541 suppresses double-strand breaks (DSB) repair, clonogenic cancer cell growth and potentiates antitumor activity of ionizing radiation in cancer cell lines. Dec 06 2023
E1638 ALKBH5 inhibitor 2 (Cpd 20m) ALKBH5 inhibitor (Cpd 20m) is a potent and selective inhibitor of RNA m6A demethylase AlkB homolog 5 ALKBH5 with IC50 of 21 nM. Dec 05 2023
A3173 Minretumomab (CC-49) Minretumomab (CC-49) is a monoclonal antibody against TAG-72 (tumor-associated glycoprotein 72). Minretumomab can be used in cancer and immunity research. Dec 04 2023
A2136 Anti-mouse CD40-InVivo Anti-mouse CD40-InVivo reacts with mouse CD40 also known as Bp50. CD40 is a type I transmembrane glycoprotein that belongs to the tumor necrosis factor receptor (TNFR) superfamily. Dec 04 2023
A2137 Anti-mouse CD8β (Lyt 3.2)-InVivo Anti-mouse CD8β (Lyt 3.2)-InVivo reacts with mouse CD8β also known as Lyt 3.2. The CD8 antigen is a transmembrane glycoprotein that acts as a co-receptor for the T cell receptor (TCR). Dec 04 2023
A2138 Anti-mouse IL-2-InVivo Anti-mouse IL-2-InVivo reacts with mouse IL-2, a cytokine that is mainly produced by T cells in response to antigenic or mitogenic stimulation Dec 04 2023
A2140 Anti-mouse/human/rat CD47 (IAP)-InVivo Anti-mouse/human/rat CD47 (IAP)-InVivo reacts with mouse CD47 otherwise known as integrin-associated protein (IAP). CD47 is an approximately 50 kDa glycosylated five transmembrane protein that is ubiquitously expressed by both hematopoietic cells such as T and B lymphocytes, monocytes, platelets and erythrocytes and non-hematopoietic cells. Dec 04 2023
E1603 ACT001(DMAMCL) ACT001(DMAMCL, dimethylaminomicheliolide) is a PAI-1 inhibitor and exerts antitumor effects on neuroblastoma (NB) both in vitro and in vivo. It also exerts synergistic effects in combination with cisplatin through the inhibition of the PAI-1/PI3K/AKT pathway. Nov 29 2023
E1497 Tulmimetostat Tulmimetostat (CPI-0209) is an orally bioavailable and selective inhibitor of EZH2 that has therapeutic potential for androgen receptor-dependent prostate cancer. Nov 26 2023
E4037 L-Canavanine sulfate L-Canavanine sulfate is a selective inhibitor of inducible NO synthase. L-Canavanine sulfate exhibits IC50 values ranging from 5 to 10 mM in arginine-rich media and causes a limited degree of cytotoxicity in HeLa, Hep G2, and SK-HEP-1 cells. Nov 26 2023
E1731 JW74 JW74 is a specific inhibitor of the canonical Wnt signaling with IC50 790 nM in the ST-Luc assay. It inhibit the growth of tumor cells in both mouse xenograft model of colorectal cancer and in ApcMin mice. Nov 26 2023